Indivior Pharmaceuticals (INDV) Net Cash Flow (2024 - 2026)

Indivior Pharmaceuticals' Net Cash Flow history runs 3 years deep, the most recent figure standing at -$21.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 139.62% year-over-year to -$21.0 million in Q1 2026; TTM through Mar 2026 was -$197.0 million, a 258.87% decrease from a year earlier, with the FY2025 full-year figure at -$123.0 million, down 4200.0% from the prior year.
• Net Cash Flow rose to -$21.0 million in Q1 2026 per INDV's latest filing, from -$250.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $136.0 million in Q2 2025 and bottomed at -$250.0 million in Q4 2025.
• The 3-year median for Net Cash Flow is -$14.0 million (2024), against an average of -$15.7 million.
• Biggest YoY gain for Net Cash Flow was 177.94% in 2025; the steepest drop was 906.45% in 2025.
• Year by year, Net Cash Flow stood at $31.0 million in 2024, then plunged by 906.45% to -$250.0 million in 2025, then surged by 91.6% to -$21.0 million in 2026.
• Per Business Quant, the three latest INDV Net Cash Flow figures stand at -$21.0 million (Q1 2026), -$250.0 million (Q4 2025), and -$62.0 million (Q3 2025).